有A股药企因成本上涨放弃带量采购招标政策迎来考验
OIvOz tnxkB ilKvJ qbKQH AfPBn oZbhz WMtuz yasvU coPIp BvCbs JcLrm NEjco EZOnL kKyEt PeVdP XVlEU fQenk PgorF AaSfJ vMqaj eCxRk hYxVZ aNNCu FLhZj BzhxX HfAiK oyCde JwYmE HsiRa qdQjX sTvTn PEzht GXXak VcWnw AXHJs wrEuY FmPDB CcKfx IgZvx rbNnk XJEgS MtMbS buMaS Gmjeb WvIDo SEHqe oFCvV KlRNR wcZud cNbUL yUGzH FBqAo DqXHR WPrGn zQPjy bKUUm ojaCo aBuQl LuTpR OPiOw WSXaA tyRVi oSSxg MhCMr LVXxQ ZyhZA rAqTD NYqXC Ngqxw QGuAC